The estimated Net Worth of Path Capital Lp Greenspan D... is at least $21.5 Milione dollars as of 3 June 2021. Path D owns over 961,538 units of Cyclerion Therapeutics stock worth over $21,508,591 and over the last 3 years Path sold CYCN stock worth over $0.
Sign up
Path D CYCN stock SEC Form 4 insiders trading
Path has made over 1 trades of the Cyclerion Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Path bought 961,538 units of CYCN stock worth $2,999,999 on 3 June 2021.
The largest trade Path's ever made was buying 961,538 units of Cyclerion Therapeutics stock on 3 June 2021 worth over $2,999,999. On average, Path trades about 961,538 units every 0 days since 2021. As of 3 June 2021 Path still owns at least 7,157,601 units of Cyclerion Therapeutics stock.
You can see the complete history of Path D stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Cyclerion Therapeutics
Over the last 6 years, insiders at Cyclerion Therapeutics have traded over $240,273 worth of Cyclerion Therapeutics stock and bought 4,653,203 units worth $33,009,775 . The most active insiders traders include Peter M Hecht, Mark G Currie e Terrance Mcguire. On average, Cyclerion Therapeutics executives and independent directors trade stock every 84 days with the average trade being worth of $749,841. The most recent stock trade was executed by Terrance Mcguire on 9 August 2023, trading 8 units of CYCN stock currently worth $27.
What does Cyclerion Therapeutics do?
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
What does Cyclerion Therapeutics's logo look like?
Complete history of Path D stock trades at Cyclerion Therapeutics
Cyclerion Therapeutics executives and stock owners
Cyclerion Therapeutics executives and other stock owners filed with the SEC include:
-
Andreas Busch,
Chief Innovation Officer, Head of the Innovation Center -
Dr. Andreas Busch Ph.D.,
Chief Scientific Officer -
Mark Currie,
President, Chief Scientific Officer -
Marsha Fanucci,
Independent Chairman of the Board -
Terrance McGuire,
Independent Director -
Amy Schulman,
Independent Director -
George Conrades,
Independent Director -
Stephanie Lovell,
Independent Director -
Ole Isacson,
Independent Director -
Kevin Churchwell,
Independent Director -
Michael Mendelsohn,
Independent Director -
Peter Hecht,
Chief Executive Officer, Director -
Dr. Peter M. Hecht Ph.D.,
CEO, Interim CFO, Principal Accounting Officer & Director -
William Huyett,
Chief Financial Officer -
Jennifer Chickering,
Sr. Director of Clinical Strategy -
Christopher Winrow,
Sr. Director of Clinical Devel. & Neuroscience Program Lead -
Jessica Rennekamp,
Associate Director of Corp. Communications -
Dr. Todd Milne Ph.D.,
VP of Corp. Devel. -
Cheryl Gault,
Chief Operating Officer -
Anjeza Gjino,
CFO & Corp. Sec. (Maternity Leave of Absence) -
Regina Margaret Graul,
See Remarks -
Path Capital Lp Greenspan D...,
-
Christopher I Wright,
Chief Medical Officer -
Anjeza Gjino,
Chief Financial Officer -
Errol B Desouza,
-
Pharmaceuticals Inc Ironwood,
10% owner -
Cheryl Gault,
Chief Operating Officer -
Steven Hyman,